NanoHybrids, Inc. announces the launch of PAtrace, a proprietary liposomal nanoparticle encasing a biocompatible optical absorber created to provide high resolution visualization and verification of the enhanced permeability and retention (EPR) effect in heterogeneous tumor models. The contrast agent is designed for use with photoacoustic (PA) imaging systems and produces depth-resolved 3D mapping of tumor permeability and retention without requiring significant preparation time....

NanoHybrids has been awarded $300,000 by the National Cancer Institute of the National Institutes of Health (NIH) to enhance the therapeutic efficacy of photodynamic therapy (PDT) in oral cancers using a novel nano-enabled hybrid technology.

Siva Therapeutics is pleased to announce that its Targeted Hyperthermia™ technology has successfully passed through the first stages of nanoparticle characterization at the Frederick National Laboratory (FNL) for Cancer Research in Frederick, Md.

FNL’s Nanotechnology Characterization Laboratory (NCL) – a partnership with the U.S. Food and Drug Administration and the National Institute of Standards and Technology – is a world leader in the characterization of therapeutic nanoparticles, which helps pave the way for regulatory review of nanotechnologies intended for cancer therapies and diagnostics.

For a limited time NanoHybrids is accepting applications for a chance to win a supply of their top Gold Nanoparticles to enhance imaging project results.

NanoHybrids has launched a contest to give promising research free premium gold nanoparticles. Targetingbiomedical imaging applications, the contest offers free nanoparticles as well as various services to winning study or research proposals. Called the NanoHybrids Imaging Research Contest, applications are being accepted now until July 31^st through the NanoHybrids website....

NanoHybrids Inc., a nanotechnology and molecular imaging company, recently received $225,000 from the National Cancer Institute (NCI) to develop a new breakthrough immunohistochemistry (IHC) technology.

The project builds on NanoHybrids expertise producing high quality gold nanoparticles that enable innovative approaches to imaging. With this Phase I Small Business Innovation Research (SBIR) grant, NanoHybrids will develop a new photoacoustic microscopy platform to quantitatively assess biomarker distribution in biopsied and histological human samples. 

“Should we try and make our own gold nanoparticles or buy them from a supplier?”

If you work with gold nanoparticles, you have probably considered this question.

NanoHybrids Inc has released a new white paper titled “Gold Nanoparticles: To Make or To Buy? A quick look at the economics behind the decision.” The paper is available for free download at the company’s website. The paper takes an in-depth look at various costs involved in making gold nanoparticles by dividing the process into two main phases - the research phase that involves fine-tuning protocols and characterization and the actual production phase....

NanoHybrids Corporation, a provider of nanotechnology-based contrast agents announced the launch of its new website and premium product line of gold nanoparticles specially designed to improve imaging results.

The company’s initial technology platform was developed in collaboration with researchers from the Biomedical Engineering Department at The University of Texas at Austin and M.D. Anderson Cancer Center.  “Frustrated by inconsistent imaging results due to highly variable shape, size and other properties of commercially available gold nanoparticle contrast agents, our team has developed highly monodisperse gold nanorods and nanospheres that will help scientists obtain consistent and better quality data....